Krystal Biotech, Inc.

Management intends to fund future operations through its on hand cash and cash equivalents and revenue generated from the sale of VYJUVEK, and may also seek additional capital through arrangements with strategic partners, the sale of equity, debt financings or other sources.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026

With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Enrollment is ongoing in the Company s KYANITE-1 study, a Phase 1 2 open label, multi-center, dose escalation and expansion study evaluating inhaled KB707 in patients with locally advanced or metastatic solid tumors of the lung.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Intratumoral KB707 for the treatment of injectable solid tumors The Company continues to enroll in OPAL-1, a Phase 1 2 open label, multi-center, dose escalation and expansion study evaluating intratumoral KB707 in patients with locally advanced or metastatic solid tumor malignancies.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

KB301 for the treatment of aesthetic indications With the prioritization of KB304 development for the treatment of wrinkles of the d collet , Jeune is now evaluating alternate aesthetic conditions most suitable for the advanced clinical development of KB301.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Jeune previously reported positive safety and efficacy results for KB301 in the treatment of multiple priority aesthetic sites of the face and body, as well as confirmation of COL3A1 gene delivery, as part of the now completed PEARL-1 Phase 1 study.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties associated with regulatory review of clinical trials and applications for marketing approvals the availability or commercial potential of VYJUVEK or product candidates and such other important factors as are set forth under the caption Risk Factors in the Company s annual and quarterly reports on file with the U.

SEC original ↗Krystal Biotech, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Legal Proceedings 30 Item 1A.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Legal Proceedings In the ordinary course of business, the Company is subject from time to time to various proceedings, lawsuits, disputes, or claims.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026

On May 29, 2026, Jonathan Forman filed a lawsuit against the Company in the United States District Court for the District of Delaware (Docket No.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026

federal and state deferred tax assets due to historical cumulative losses and uncertainty regarding the realization of such assets.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026

These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

SEC original ↗Krystal Biotech, Inc. — 10-Q Quarterly report10-QAug 3, 2026